Effects of EGFR inhibition with tyrosine kinase inhibitors on invasive properties of EGFR mutant and wild type lung cancer cells

被引：0
|
作者：
Umelo, I. A. [1 ,2 ]
De Wever, O. [3 ,4 ]
Teugels, E. [1 ,2 ]
Bracke, M. [3 ,4 ]
De Greve, J. [1 ,2 ]
机构：
[1] Univ Ziekenhuis Brussel, Mol Oncol Lab, Brussels, Belgium
[2] Dept Med Oncol, Brussels, Belgium
[3] Univ Ziekenhuis Ghent, Lab Expt Canc Res, Ghent, Belgium
[4] Dept Radiotherapy, Ghent, Belgium
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：68 / 68
页数：1
相关论文
共 50 条
  • [1] The Effect of Acquired Cisplatin Resistance on Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR Mutant Lung Cancer Cells
    Rho, Jin Kyung
    Choi, Yun Jung
    Choi, You Ri
    Kim, Sun Ye
    Choi, Su Jin
    Choi, Chang-Min
    Na, Im Il
    Lee, Jae Cheol
    [J]. ONCOLOGY RESEARCH, 2011, 19 (10-11) : 471 - 478
  • [2] The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
    Thomas E. Stinchcombe
    [J]. Current Treatment Options in Oncology, 2016, 17
  • [3] The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
    Stinchcombe, Thomas E.
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (04)
  • [4] THE EFFECT OF ACQUISITION OF CISPLATIN-RESISTANCE ON SENSITIVITY TO EGFR TYROSINE KINASE INHIBITORS IN EGFR MUTANT LUNG CANCER CELLS
    Lee, J. C.
    Rho, J. K.
    Choi, Y. J.
    Koh, J. S.
    Chung, H. S.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 61 - 61
  • [5] Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells
    Tabara, Keisuke
    Kanda, Rina
    Sonoda, Kahori
    Kubo, Takuya
    Murakami, Yuichi
    Kawahara, Akihiko
    Azuma, Koichi
    Abe, Hideyuki
    Kage, Masayoshi
    Yoshinaga, Aki
    Tahira, Tomoko
    Hayashi, Kenshi
    Arao, Tokuzo
    Nishio, Kazuto
    Rosell, Rafael
    Kuwano, Michihiko
    Ono, Mayumi
    [J]. PLOS ONE, 2012, 7 (07):
  • [6] Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer
    Park, Siyeon
    Park, Seongyeol
    Kim, Tae Min
    Kim, Soyeon
    Koh, Jaemoon
    Lim, Joonoh
    Yi, Kijong
    Yi, Boram
    Ju, Young Seok
    Kim, Miso
    Keam, Bhumsuk
    Kim, Jung Sun
    Jeon, Yoon Kyung
    Kim, Dong-Wan
    Kim, Young Tae
    Heo, Dae Seog
    [J]. EUROPEAN JOURNAL OF CANCER, 2024, 208
  • [7] Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer
    A Choughule
    R Sharma
    V Trivedi
    A Thavamani
    V Noronha
    A Joshi
    S Desai
    P Chandrani
    P Sundaram
    S Utture
    N Jambhekar
    S Gupta
    J Aich
    K Prabhash
    A Dutt
    [J]. British Journal of Cancer, 2014, 111 : 2203 - 2204
  • [8] Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer
    Choughule, A.
    Sharma, R.
    Trivedi, V.
    Thavamani, A.
    Noronha, V.
    Joshi, A.
    Desai, S.
    Chandrani, P.
    Sundaram, P.
    Utture, S.
    Jambhekar, N.
    Gupta, S.
    Aich, J.
    Prabhash, K.
    Dutt, A.
    [J]. BRITISH JOURNAL OF CANCER, 2014, 111 (11) : 2203 - 2204
  • [9] Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine Kinase Inhibitors
    Thomas, Rintu
    Srivastava, Shivangi
    Katreddy, Rajasekhara Reddy
    Sobieski, Jason
    Weihua, Zhang
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (10)
  • [10] Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
    Choi, Yun Jung
    Park, Gun Min
    Rho, Jin Kyung
    Kim, Sun Ye
    So, Gwang Sup
    Kim, Hyeong Ryul
    Choi, Chang-Min
    Lee, Jae Cheol
    [J]. PLOS ONE, 2013, 8 (12):
12345